Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA names new head of biosimilars unit

This article was originally published in Scrip

Executive Summary

Darmstadt, Germany-headquartered Merck KGaA has named Boehringer Ingelheim's former head of biopharmaceuticals, Simon Sturge, head of its biosimilars unit – effective 1 March 2014. Mr Sturge will be based at the unit in Canton de Vaud, Switzerland and will report to Stefan Oschmann, a member of Merck's executive board responsible for the company's pharmaceutical businesses. Prior to Boehringer Ingelheim Mr Sturge was CEO of Dutch biotech-company OctoPlus.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC024504

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel